109 related articles for article (PubMed ID: 16619587)
1. Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations.
Dollner R; Granzow C; Neudert M; Dietz A
Anticancer Res; 2006; 26(2B):1651-5. PubMed ID: 16619587
[TBL] [Abstract][Full Text] [Related]
2. The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma.
Dollner R; Granzow C; Helmke BM; Ruess A; Schad A; Dietz A
Anticancer Res; 2004; 24(1):325-31. PubMed ID: 15015616
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse.
Horn IS; Wichmann G; Mozet C; Dietz A; Dollner R; Tschöp K; Boehm A
Cancer Chemother Pharmacol; 2010 May; 65(6):1153-63. PubMed ID: 19771432
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo responsiveness of head and neck squamous cell carcinoma to vinorelbine.
Dollner R; Granzow C; Tschop K; Dietz A
Anticancer Res; 2006; 26(3B):2361-5. PubMed ID: 16821617
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics.
Stoehr M; Mozet C; Boehm A; Aigner A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2014 Apr; 73(4):827-37. PubMed ID: 24562588
[TBL] [Abstract][Full Text] [Related]
6. Single tissue samples from head and neck squamous cell carcinomas are representative regarding the entire tumor's chemosensitivity to cisplatin and docetaxel.
Wichmann G; Horn IS; Boehm A; Mozet C; Tschop K; Dollner R; Dietz A
Onkologie; 2009 May; 32(5):264-72. PubMed ID: 19420973
[TBL] [Abstract][Full Text] [Related]
7. [Results of a phase II study with the new cytostatic drug carboplatin in combination with 5-fluorouracil in the primary treatment of advanced squamous cell cancers of the head and neck].
Volling P; Schröder M; Rauschning W; Achterrath W; Stennert E; Nagel G
HNO; 1988 Nov; 36(11):452-5. PubMed ID: 3069815
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma.
Schrader C; Boehm A; Reiche A; Dietz A; Mozet C; Wichmann G
Anticancer Res; 2012 Aug; 32(8):3191-9. PubMed ID: 22843892
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
Budach W; Hehr T; Budach V; Belka C; Dietz K
BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551
[TBL] [Abstract][Full Text] [Related]
12. Drug response of head and neck tumors in native-state histoculture.
Robbins KT; Varki NM; Storniolo AM; Hoffman H; Hoffman RM
Arch Otolaryngol Head Neck Surg; 1991 Jan; 117(1):83-6. PubMed ID: 1986767
[TBL] [Abstract][Full Text] [Related]
13. EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Knecht R; Peters S; Solbach C; Baghi M; Gstöttner W; Hambek M
Anticancer Res; 2003; 23(6C):4789-95. PubMed ID: 14981927
[TBL] [Abstract][Full Text] [Related]
14. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent.
Dollner R; Dietz A; Kopun M; Helbig M; Wallner F; Granzow C
Anticancer Res; 2004; 24(5A):2947-51. PubMed ID: 15517901
[TBL] [Abstract][Full Text] [Related]
16. Stimulation by Monocyte Chemoattractant Protein-1 Modulates the Ex-vivo Colony Formation by Head and Neck Squamous Cell Carcinoma Cells.
Wichmann G; Körner C; Boehm A; Mozet C; Dietz A
Anticancer Res; 2015 Jul; 35(7):3917-24. PubMed ID: 26124338
[TBL] [Abstract][Full Text] [Related]
17. Hedgehog targeting by cyclopamine suppresses head and neck squamous cell carcinoma and enhances chemotherapeutic effects.
Mozet C; Stoehr M; Dimitrova K; Dietz A; Wichmann G
Anticancer Res; 2013 Jun; 33(6):2415-24. PubMed ID: 23749890
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Haddad R; Colevas AD; Tishler R; Busse P; Goguen L; Sullivan C; Norris CM; Lake-Willcutt B; Case MA; Costello R; Posner M
Cancer; 2003 Jan; 97(2):412-8. PubMed ID: 12518365
[TBL] [Abstract][Full Text] [Related]
19. Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Terada A; Hyodo I; Ogawa T; Fukushima M
Oncology; 2007; 73(1-2):104-11. PubMed ID: 18337622
[TBL] [Abstract][Full Text] [Related]
20. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
Posner MR; Colevas AD; Tishler RB
Semin Oncol; 2000 Aug; 27(4 Suppl 8):13-24. PubMed ID: 10952434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
